- Home
- SAND vs IMCR Comparison
SAND vs IMCR Comparison
Compare SAND & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAND
- IMCR
- Stock Information
- Founded
- SAND 2007
- IMCR 2008
- Country
- SAND Canada
- IMCR United Kingdom
- Employees
- SAND N/A
- IMCR N/A
- Industry
- SAND
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SAND
- IMCR Health Care
- Exchange
- SAND NYSE
- IMCR Nasdaq
- Market Cap
- SAND 2.4B
- IMCR 1.5B
- IPO Year
- SAND N/A
- IMCR 2021
- Fundamental
- Price
- SAND $9.41
- IMCR $31.15
- Analyst Decision
- SAND Buy
- IMCR Buy
- Analyst Count
- SAND 4
- IMCR 10
- Target Price
- SAND $9.13
- IMCR $58.13
- AVG Volume (30 Days)
- SAND 5.2M
- IMCR 473.9K
- Earning Date
- SAND 07-31-2025
- IMCR 08-07-2025
- Dividend Yield
- SAND 0.67%
- IMCR N/A
- EPS Growth
- SAND 32.83
- IMCR N/A
- EPS
- SAND 0.10
- IMCR N/A
- Revenue
- SAND $183,537,000.00
- IMCR $333,581,000.00
- Revenue This Year
- SAND $17.55
- IMCR $26.82
- Revenue Next Year
- SAND $10.62
- IMCR $8.15
- P/E Ratio
- SAND $96.14
- IMCR N/A
- Revenue Growth
- SAND 2.84
- IMCR 25.75
- 52 Week Low
- SAND $4.92
- IMCR $23.15
- 52 Week High
- SAND $9.68
- IMCR $41.54
- Technical
- Relative Strength Index (RSI)
- SAND 59.45
- IMCR 44.46
- Support Level
- SAND $8.95
- IMCR $30.83
- Resistance Level
- SAND $9.43
- IMCR $37.56
- Average True Range (ATR)
- SAND 0.23
- IMCR 1.58
- MACD
- SAND -0.03
- IMCR -0.59
- Stochastic Oscillator
- SAND 96.61
- IMCR 15.64
About SAND SANDSTORM GOLD LIMITED
Sandstorm Gold Ltd provides financing to companies engaged in gold mining through the gold stream and royalty. Geographically, the company has operational footprints in North America, South & Central America, Africa, and Asia & Australia. The firm's royalties include Hod Maden, Santa Elena, Chapada, Platreef, Greenstone, and Cerro Moro.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.